Foetal congenital heart defects can triple risk of preeclampsia, preterm birth: Study
New Delhi, Dec 20 (IANS) Foetus suffering from major congenital heart defects (MCHDs) may triple the risk of adverse pregnancy outcomes such as preeclampsia and preterm birth, finds a study. MCHDs occur in approximately 1 in 100 live births, and can negatively impact both the health of the mother and the long-term outcomes for the
New Delhi, Dec 20 (IANS) Foetus suffering from major congenital heart defects (MCHDs) may triple the risk of adverse pregnancy outcomes such as preeclampsia and preterm birth, finds a study.
MCHDs occur in approximately 1 in 100 live births, and can negatively impact both the health of the mother and the long-term outcomes for the child.
Researchers from the Statens Serum Institut in Copenhagen showed that about 23 per cent of pregnancies affected by foetal MCHD also result in adverse obstetric outcomes including preeclampsia, preterm birth, fetal growth restriction, and placental abruption.
The findings were based on data from 534,170 pregnancies, including 745 cases complicated by foetal MCHDs in Denmark. Pregnancies resulting in live births after 24 gestational weeks and without chromosomal aberrations were included in the study.
The study, published in JAMA Pediatrics, also assessed 11 MCHD subtypes, including univentricular heart, transposition of the great arteries (TGA), and atrioventricular septal defect.
Data on the obstetric risk profile for specific MCHD subtypes are limited and thus slow down the development of preventive interventions.
Pregnancies complicated by MCHDs suffered an adverse obstetric outcome rate of 22.8 per cent.
While foetal growth restriction occurred in 6.7 per cent of MCHD pregnancies, a higher prevalence of preeclampsia was found in 6.2 per cent of MCHD pregnancies.
They also found a 15.7 per cent increased risk of preterm births in MCHD pregnancies. While Placental abruption was rare it showed a significant trend toward higher incidence 0.9 per cent.
All MCHD subtypes, except TGA, were associated with significantly higher odds of the composite adverse outcome. The highest risk was observed in pregnancies with truncus arteriosus, pulmonary atresia with intact ventricular septum, and Ebstein anomaly.
The team also confirmed the findings with a meta-analysis of 5,993 cases of MCHDs. Notably, pregnancies with fetal TGA did not exhibit elevated risks of preeclampsia, preterm birth, or fetal growth restriction, the findings showed.
–IANS
rvt/
ମୁଖ୍ୟ ଶାସନ ସଚିବଙ୍କ ଅଧ୍ୟକ୍ଷତାରେ ସଚିବସ୍ତରୀୟ ବୈଠକ ଅନୁଷ୍ଠିତ
Next ArticleNaveen Condoles Demise of Former Haryana CM Om Prakash Chautala
Related Articles
New AI tool to revolutionise personalised cancer treatment

स्वास्थ्य व लाइफस्टाइलNew AI tool to revolutionise personalised cancer treatment
New Delhi: An international team of scientists has developed an artificial intelligence (AI) tool that could revolutionise cancer treatment by mapping cellular diversity within tumours. The innovation tackles tumour heterogeneity in oncology, where varied cell populations cause treatment resistance and recurrence, Xinhua news agency reported. The AAnet AI tool, developed by the Sydney-based Garvan Institute
Covid-19 virus protein triggers immune attack on healthy cells: Study

स्वास्थ्य व लाइफस्टाइलCovid-19 virus protein triggers immune attack on healthy cells: Study
New Delhi: Amid a fresh wave of Covid-19, Israeli researchers have discovered that a protein from the SARS-CoV-2 virus can cause the immune system to attack healthy cells mistakenly. The study, published in the journal Cell Reports, sheds light on how severe Covid complications may occur and suggests new ways to prevent immune-driven damage from
Global AI collaboration revolutionises personalised cancer treatment

स्वास्थ्य व लाइफस्टाइलGlobal AI collaboration revolutionises personalised cancer treatment
New Delhi: An international team of scientists has unveiled an artificial intelligence (AI) technique that securely analyses global cancer samples, paving the way for more personalised and privacy-protected cancer treatments. This innovative approach promises to accelerate personalised cancer treatment by enabling clinicians to match therapies to individual patients better, Xinhua news agency reported. The study
